drugset / Trial / NCT01923220

Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis

NCT01923220 ↗

Phase 0 Unknown 90 enrolled HealOr
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a single-center, open-label, randomized, prospective study evaluating the safety and efficacy of HO/02/02 20µg topically applied daily for 15 minutes (with gauze) on treatment fields vs. standard of care (SoC), Aloe Vera treatment

Timeline

Start
2013-09
Primary completion
2014-09
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject HO/02/02 Unknown 20 ug Topical

Indications